Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF - fidaxomicin for C. difficile
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
Qualitative no-adjustment guidance.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: Qualitative no-adjustment guidance. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
For adult C. difficile infection, the dose is 200 mg orally every 12 hours. UCSF retains this schedule in renal dysfunction and hemodialysis. Select the CDI treatment course under the applicable infection guideline; this is not systemic antibacterial treatment.
RDM30-038-fidaxomicin-1 · Source locator: UCSF - fidaxomicin for C. difficile; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.